Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy

被引:184
|
作者
King, W. M.
Ruttencutter, R.
Nagaraja, H. N.
Matkovic, V.
Landoll, J.
Hoyle, C.
Mendell, J. R.
Kissel, J. T.
机构
[1] Ohio State Univ, Med Ctr, Dept Neurol, Div Neuromuscular Dis, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Internal Med Phys Med & Rehabil, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Stat, Columbus, OH 43210 USA
关键词
D O I
10.1212/01.wnl.0000260974.41514.83
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To document the effects of long- term daily corticosteroid treatment on a variety of orthopedic outcomes in boys with Duchenne muscular dystrophy. Methods: We reviewed the charts of 159 boys with genetically confirmed dystrophinopathies followed at the Ohio State University Muscular Dystrophy Clinic between 2000 and 2003. Charts were reviewed for ambulation status, type and duration of steroid treatment (if any), and orthopedic complications including presence and location of long bone fractures, vertebral compression fractures, and the presence and degree of scoliosis. Results: The cohort consisted of 143 boys (16 boys with Becker dystrophy were excluded); 75 had been treated with steroids for at least 1 year, whereas 68 boys had never been treated or had received only a brief submaximal dose. The mean duration of daily steroid treatment was 8.04 years. Treated boys ambulated independently 3.3 years longer than the untreated group (p < 0.0001) and had a lower prevalence of scoliosis than the untreated group (31 vs 91%; p < 0.0001). The average scoliotic curve was also milder in the treated group (11.6 degrees) compared with the untreated group (33.2 degrees; p < 0.0001). Vertebral compression fractures occurred in 32% of the treated group, whereas no vertebral fractures were discovered in the steroid naive group (p = 0.0012). Long bone fractures were 2.6 times greater in steroid- treated patients. Conclusions: Although boys with Duchenne muscular dystrophy on long- term corticosteroid treatment have a significantly decreased risk of scoliosis and an extension of more than 3 years' independent ambulation, they are at increased risk of vertebral and lower limb fractures compared with untreated boys.
引用
收藏
页码:1607 / 1613
页数:7
相关论文
共 50 条
  • [41] Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy
    Lamb, Molly
    West, Nancy
    Ouyang, Lijing
    Yang, Michele
    Weitzenkamp, David
    James, Katherine
    Ciafaloni, Emma
    Pandya, Shree
    Fox, Deborah
    DiGuiseppi, Carolyn
    [J]. NEUROLOGY, 2016, 86
  • [42] Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy
    Markham, Larry W.
    Kinnett, Kathi
    Wong, Brenda L.
    Benson, D. Woodrow
    Cripe, Linda H.
    [J]. NEUROMUSCULAR DISORDERS, 2008, 18 (05) : 365 - 370
  • [43] Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy
    Lamb, Molly M.
    West, Nancy A.
    Ouyang, Lijing
    Yang, Michele
    Weitzenkamp, David
    James, Katherine
    Ciafaloni, Emma
    Pandya, Shree
    DiGuiseppi, Carolyn
    [J]. JOURNAL OF PEDIATRICS, 2016, 173 : 207 - +
  • [44] Glucocorticoid Treatment for the Prevention of Scoliosis in Children with Duchenne Muscular Dystrophy: Long-Term Follow-up
    Lebel, David E.
    Corston, John A.
    McAdam, Laura C.
    Biggar, W. Douglas
    Alman, Benjamin A.
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2013, 95A (12): : 1057 - 1061
  • [45] Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)
    Mayer, Oscar Henry
    Leinonen, Mika
    Servais, Laurent
    Straathof, Chiara
    Schara, Ulrike
    Voit, Thomas
    Mercuri, Eugenio
    Buyse, Gunnar
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [46] Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy
    Finsterer, Josef
    Stoellberger, Claudia
    [J]. NEUROMUSCULAR DISORDERS, 2009, 19 (01) : 74 - 74
  • [47] Side effects of long-term prednisone treatment in Duchenne dystrophy
    Pandya, S
    Moxley, RT
    Griggs, RC
    King, W
    Signore, L
    Mendell, JR
    Kissel, JT
    Florence, J
    Schierbecker, J
    Pestronk, A
    Robinson, J
    Fenichel, G
    Mathieson-Burden, N
    Brooke, MH
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (03) : 469 - 469
  • [48] Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies
    Wang, Mary
    Birnkrant, David J.
    Super, Dennis M.
    Jacobs, Irwin B.
    Bahler, Robert C.
    [J]. OPEN HEART, 2018, 5 (01):
  • [49] Orthopedic Interventions for Foot Deformities in Non-Ambulant People with Duchenne Muscular Dystrophy: A Retrospective Study on Indications, Post-Operative and Long-Term Outcomes
    Houwen-van Opstal, Saskia L. S.
    Timmer, Amity C.
    Ten Ham, A. M.
    Hosman, Allard J. F.
    Willemsen, Michel A. A. P.
    de Groot, Imelda J. M.
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (05) : 641 - 648
  • [50] Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy
    Tian, Cuixia
    Wong, Brenda L.
    Hornung, Lindsey
    Khoury, Jane C.
    Rybalsky, Irina
    Shellenbarger, Karen C.
    Rutter, Meilan M.
    [J]. NEUROMUSCULAR DISORDERS, 2020, 30 (07) : 599 - 610